Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
暂无分享,去创建一个
Raul Rabadan | Robin Foà | Hossein Khiabanian | Davide Rossi | Silvia Rasi | Jiguang Wang | R. Rabadán | R. Foà | Hossein Khiabanian | D. Rossi | G. Gaidano | A. Guarini | Jiguang Wang | S. Rasi | S. Monti | V. Gattei | Gianluca Gaidano | C. Ciardullo | Anna Guarini | Valter Gattei | L. De Paoli | C. Deambrogi | V. Spina | A. Bruscaggin | R. Famà | Lorenzo De Paoli | Sara Monti | Valeria Spina | Alessio Bruscaggin | Carmela Ciardullo | Rosella Famà | Clara Deambrogi | Carmela Ciardullo | Rosella Famà
[1] Axel Benner,et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.
[2] J F Lawless,et al. Regression and recursive partition strategies in the analysis of medical survival data. , 1988, Journal of clinical epidemiology.
[3] David A. Schoenfeld,et al. Partial residuals for the proportional hazards regression model , 1982 .
[4] ONSTANZE,et al. GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .
[5] P. Ouillette,et al. Clonal Evolution, Genomic Drivers, and Effects of Therapy in Chronic Lymphocytic Leukemia , 2013, Clinical Cancer Research.
[6] C. C. Chen,et al. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. , 1985, Statistics in medicine.
[7] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[8] R. Tibshirani,et al. Improvements on Cross-Validation: The 632+ Bootstrap Method , 1997 .
[9] R. Dalla‐Favera,et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.
[10] Schraga Schwartz,et al. Detection and Removal of Biases in the Analysis of Next-Generation Sequencing Reads , 2011, PloS one.
[11] G. Morgan,et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Daniel B. Mark,et al. TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .
[13] A. Tsimberidou,et al. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , 2013 .
[14] A. Kohlmann,et al. Robustness of amplicon deep sequencing underlines its utility in clinical applications. , 2013, The Journal of molecular diagnostics : JMD.
[15] D. Rossi,et al. The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.
[16] D.,et al. Regression Models and Life-Tables , 2022 .
[17] Jan Albert,et al. PCR-Induced Transitions Are the Major Source of Error in Cleaned Ultra-Deep Pyrosequencing Data , 2013, PloS one.
[18] A. Pettitt,et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations , 2010, Leukemia.
[19] J. Gmür. [Indications for allogeneic and autologous bone marrow transplantation]. , 1991, Schweizerische medizinische Wochenschrift.
[20] E. Kimby,et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus , 2007, Leukemia.
[21] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[22] S. Carter,et al. Clonal evolution in hematological malignancies and therapeutic implications , 2014, Leukemia.
[23] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[24] L. Medeiros,et al. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , 2013 .
[25] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[26] A. Pettitt,et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia , 2012, British journal of haematology.
[27] M. Iacono,et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. , 2013, Blood.
[28] Jenny Taylor,et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.
[29] R. Foà,et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. , 2012, Blood.
[30] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[31] M. Gerstung,et al. Reliable detection of subclonal single-nucleotide variants in tumour cell populations , 2012, Nature Communications.
[32] A. Moya,et al. Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity. , 1998, The Journal of general virology.
[33] S. Kato,et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[34] A. Jauch,et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia , 2013, British journal of haematology.
[35] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[36] Rafael A Irizarry,et al. Overcoming bias and systematic errors in next generation sequencing data , 2010, Genome Medicine.
[37] H. Döhner,et al. TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[39] H. Döhner,et al. How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance , 2008, Leukemia.
[40] S. Lewis,et al. British Committee for Standards in Haematology , 1969 .
[41] J. Gribben,et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. , 2012, Blood.
[42] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[43] M. Stratton,et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing , 2008, Proceedings of the National Academy of Sciences.
[44] J. C. van Houwelingen,et al. Predictive value of statistical models , 1990 .
[45] J. Gribben,et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia , 2012, Leukemia.
[46] T. Dallman,et al. Performance comparison of benchtop high-throughput sequencing platforms , 2012, Nature Biotechnology.